Variation in tumor cell content as described by PCA.

<p>(A) The score plot of the pre-processed spectra, colored according to the tumor cell content (%) of the corresponding biopsies. (B) The corresponding loading profile of PC1, explaining 40.1% of the total variation of the data. β-Glc, β-glucose; Asc, ascorbate; Lac, lactate; Cr, creatine; Gly, glycine; Tau, taurine; GPC, glycerophosphocholine; PCho, phosphocholine; Cho, free choline.</p

PLS- DA classification of tumor and non-involved tissue.

<p>(A) The score plot, separating tumor and non-involved tissue, and (B) the corresponding loading profiles of LV1 and LV2. LV1 and LV2 explain 35.8% and 13.2% of the x-variation and 53.3% and 4.9% of the y-variation, respectively. β-Glc, β-glucose; Asc, ascorbate; Lac, lactate; Cr, creatine; Gly, glycine; Tau, taurine; GPC, glycerophosphocholine; PCho, phosphocholine; Cho, free choline.</p

Patient characteristics.

*<p>Ductal carcinoma in situ, mucinous carcinoma, several diagnoses.</p>**<p>Estrogen receptor status.</p>***<p>Progesterone receptor status.</p

Variation in tumor cell content as described by PCA of the choline region.

<p>(A) The score plot of the choline-containing metabolite region of the spectra, colored according to the tumor cell content (%) of the corresponding biopsies. (B) The corresponding loading profile of PC1 explaining 71.3% of the total variation of the data.</p

HR MAS spectra and illustration of typical features observed in the corresponding HES images (200X).

<p>(A) Invasive ductal carcinoma with an estimated tumor content of 80% in the analysed biopsy. (B) Invasive mucinous carcinoma with an estimated tumor content of 60% in the analysed biopsy. (C) Normal breast tissue (adjacent to tumor). No tumor cells were detected, and the HES image shows the typical feature of normal terminal lobular duct units. The poor signal to noise ratio in this spectrum is probably due to the high level of connective tissue (85%).</p

Tissue composition of the biopsies for the study cohort.

<p>Tissue composition of the biopsies for the study cohort.</p

PLS-DA classification results for separating tumor and adjacent non-involved tissue.

*<p>Samples with 0%Table 2).</p>**<p>Samples with 0%Table 2).</p><p>TC, tumor content.</p